Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279125 | 1.00 | SMO (0.56) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL1089608 | 0.88 | NPSR1 (0.63) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL1089606 | 0.88 | NPSR1 (0.63) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL2275050 | 0.86 | SMO (0.58) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL2275061 | 0.86 | SMO (0.58) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL2278195 | 0.86 | SMO (0.58) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL12435066 | 0.85 | SMO (0.40) | SMO | |
| SCHEMBL2277207 | 0.84 | NPSR1 (0.67) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL2277202 | 0.84 | NPSR1 (0.67) | SMONPSR1KMT2AMEN1HTT | |
| SCHEMBL2276732 | 0.83 | SMO (0.60) | SMONPSR1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364185-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8404687-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | SMO 3/4885NPSR1 1903/4885KMT2A 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.